Literature DB >> 12827553

A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.

Francis Y Yao1, Nathan M Bass, Bev Nikolai, Raphael Merriman, Timothy J Davern, Robert Kerlan, Nancy L Ascher, John P Roberts.   

Abstract

Since our interim report of the intention-to-treat outcome of orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), we have performed a follow-up analysis of an expanded cohort of 70 patients to further assess whether the observed pattern and predictors of dropout are consistent with the rationale behind current HCC-adjusted Model for End Stage Liver Disease (MELD) organ allocation scheme. All except one patient had pretransplantation staging meeting our proposed expanded criteria-a single lesion < or =6.5 cm, or three or fewer lesions none >4.5 cm and total tumor diameter < or =8 cm. Thirty-eight patients received OLT. The cumulative probabilities of dropout at 6, 12, and 18 months were 7.2%, 37.8%, and 55.1%, respectively. The respective dropout probabilities would have been 11.0%, 57.4%, and 68.7% if the United Network for Organ Sharing (UNOS) criteria for exclusion (single lesion < or =5 cm or three or fewer lesions none >3 cm) were applied. Predictors of dropout with either criteria included three tumor nodules and a single lesion >3 cm at initial presentation, whereas preoperative chemoembolization or ablation therapies were associated with a lower risk for dropout only when applying the UNOS criteria for patient exclusion. In the subgroup with two or three lesions or a solitary tumor >3 cm, the cumulative probabilities of dropout were nine-fold higher than those with a single lesion < or =3 cm (P =.004). In conclusion, the low dropout rate in the first 6 months and the differing dropout risks based on tumor characteristics support further refinements in the HCC-adjusted MELD organ allocation scheme.

Entities:  

Mesh:

Year:  2003        PMID: 12827553     DOI: 10.1053/jlts.2003.50147

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  54 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

Review 2.  Radioembolization for primary and metastatic liver cancer.

Authors:  Khairuddin Memon; Robert J Lewandowski; Laura Kulik; Ahsun Riaz; Mary F Mulcahy; Riad Salem
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

Review 3.  Developments in liver transplantation.

Authors:  J Neuberger
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 4.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

5.  Loco-regional treatments on the liver transplant waiting list: unmasking hepatocellular carcinoma (HCC) biology.

Authors:  Amine Benmassaoud; Emmanuel A Tsochatzis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

Review 6.  The management of patients awaiting liver transplantation.

Authors:  Ka-Kit Li; James Neuberger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-10-06       Impact factor: 46.802

7.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

Review 8.  Radiofrequency ablation of liver tumors.

Authors:  Shaunagh McDermott; Debra A Gervais
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 9.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 10.  Advances in liver transplantation allocation systems.

Authors:  Michael L Schilsky; Maryam Moini
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.